Literature DB >> 12625991

Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina.

Kristen S Langworthy-Lam1, Michael G Aman, Mary E Van Bourgondien.   

Abstract

The aim of this study was to assess the prevalence and patterns of psychoactive and over-the-counter medicines in a large cohort of individuals with autism. We conducted a mail survey of 3,228 families that are members of the Autism Society of North Carolina. This is one of the largest chapters of the Autism Society of America. The survey form addressed current medicines used, side effects, demographic characteristics, and medical conditions. Some 1,538 member families within the society (48%) responded to the survey. In all, 703 (45.7%) individuals with autism were taking psychotropic drugs, 191 (12.4%) antiepileptic drugs (AEDs), and 86 (5.7%) supplements for autism. The total number taking psychotropic, antiepileptic, or vitamin treatments was 816 (53.1%). Antidepressants (taken by 21.7% of the sample), antipsychotics (16.8%), and stimulants (13.9%) were the most commonly prescribed agents. Univariate and multivariate analyses were conducted to examine factors associated with treatment. Greater age, more severe autism and mental retardation, and more restricted housing were often associated with greater use of psychoactive agents. These findings suggest that individuals with autism are a frequently medicated group, although the empirical research support for most agents being used is still very limited.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12625991     DOI: 10.1089/104454602762599853

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  24 in total

1.  Corticosteroid and neurosteroid dysregulation in an animal model of autism, BTBR mice.

Authors:  Cheryl A Frye; Danielle C Llaneza
Journal:  Physiol Behav       Date:  2010-03-16

2.  Medical expenditures for children with an autism spectrum disorder in a privately insured population.

Authors:  Tom T Shimabukuro; Scott D Grosse; Catherine Rice
Journal:  J Autism Dev Disord       Date:  2007-08-10

3.  Mood and Anxiety Symptoms in Psychiatric Inpatients with Autism Spectrum Disorder and Depression.

Authors:  Lauren Charlot; Curtis K Deutsch; Aranya Albert; Anne Hunt; Daniel F Connor; William J McIlvane
Journal:  J Ment Health Res Intellect Disabil       Date:  2008

4.  Treatment of comorbid anxiety and autism spectrum disorders.

Authors:  Joshua Nadeau; Michael L Sulkowski; Danielle Ung; Jeffrey J Wood; Adam B Lewin; Tanya K Murphy; Jill Ehrenreich May; Eric A Storch
Journal:  Neuropsychiatry (London)       Date:  2011-12

5.  Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008.

Authors:  Rebecca E Rosenberg; David S Mandell; Janet E Farmer; J Kiely Law; Alison R Marvin; Paul A Law
Journal:  J Autism Dev Disord       Date:  2010-03

6.  Psychiatric comorbidity and medication use in adults with autism spectrum disorder.

Authors:  Tara R Buck; Joseph Viskochil; Megan Farley; Hilary Coon; William M McMahon; Jubel Morgan; Deborah A Bilder
Journal:  J Autism Dev Disord       Date:  2014-12

7.  Psychotropic drug treatments for people with autism and other developmental disorders: a primer for practicing behavior analysts.

Authors:  Marc Weeden; Kristal Ehrhardt; Alan Poling
Journal:  Behav Anal Pract       Date:  2010

8.  Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.

Authors:  Dinah S Reddihough; Catherine Marraffa; Anissa Mouti; Molly O'Sullivan; Katherine J Lee; Francesca Orsini; Philip Hazell; Joanna Granich; Andrew J O Whitehouse; John Wray; David Dossetor; Paramala Santosh; Natalie Silove; Michael Kohn
Journal:  JAMA       Date:  2019-10-22       Impact factor: 56.272

9.  Non-psychiatric health problems among psychiatric inpatients with intellectual disabilities.

Authors:  L Charlot; S Abend; P Ravin; K Mastis; A Hunt; C Deutsch
Journal:  J Intellect Disabil Res       Date:  2011-02

10.  Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.

Authors:  Michael G Aman; Alexander A Vinks; Bart Remmerie; Erik Mannaert; Yaser Ramadan; Jessica Masty; Ronald L Lindsay; Krista Malone
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.